1. Slide 1 of 5 From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Stuart C. Ray, MD, FIDSA Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Program The Johns Hopkins University School of Medicine Baltimore, Maryland Hepatitis C Virus (HCV) Coinfection: Don’t Stand Still Just Because the Landscape Looks Better From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA.

2. Slide 2 of 5 From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA. HCV DAA Glossary Generic nameCode nameClass sovaprevirACH-1625PI setrobuvirANA598NNI faldaprevirBI 201335PI daclatasvirBMS 790052NS5A asunaprevirBMS-650032PI ledipasvirGS-5885NS5A sofosbuvirGS-7977Nuc vaniprevirMK-7009PI mericitabineRG 7128Nuc danoprevirRG 7227PI boceprevirSCH 503034PI simeprevirTMC435PI telaprevirVX-950PI

3. Slide 3 of 5 From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA. DAA Regimens in Phase 3 Trials PINS5ANon- nucleoside polymerase Nucleo(t)ide polymerase RibavirinPegIFN SofosbuvirRBV+/- PegIFN alfa LedipasvirSofosbuvir+/- RBV ABT50/rABT267ABT333+/- RBV AsunaprevirDaclatasvir+/- RBV+/- PegIFN alfa SimeprevirRBVPegIFN alfa FaldaprevirRBVPegIFN alfa VaniprevirRBVPegIFN alfa Faldaprevir*BI7127RBV DaclatasvirRBVPegIFN lambda *Subgenotype 1b only

4. Slide 4 of 5 From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA. Telaprevir Added to P+R in patients with HIV and HCV-1 Sulkowski MS, et al. NEJM 2013

5. Slide 5 of 5 From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA. Resistance: Common Themes and Some Differences Nonsuppressive therapy generates resistance Combination therapy: – Reduces risk of resistance with HIV and HCV – Not required for HBV (monotherapy is effective) For HIV and HBV, resistance is “permanent” – Not known for HCV